| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jun 15, 2021 |
Chief Business Officer
Trans History: 2
|
Chief Business Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 400,000 | -- | 400,000 |
| Jun 01, 2021 |
Chief Commercial Officer
Trans History: 2
|
Chief Commercial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 400,000 | -- | 400,000 |
| Mar 06, 2023 |
General Counsel
Trans History: 4
|
General Counsel | Form 3 | Initial Statement of Beneficial Ownership of Securities | 350,000 | -- | -- |
| Sep 01, 2020 |
Chief Financial Officer
Trans History: 14
|
Chief Financial Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 350,000 | -- | 350,000 |
| Aug 23, 2018 |
Ten Percent Owner
Trans History: 20
|
Ten Percent Owner | Form 4 | Conversion of derivative security | 337,694 | $4.59 | 929,878 |
| Dec 30, 2021 |
Chief Informatics Officer
Trans History: 1
|
Chief Informatics Officer | Form 5 | Bona fide gift | 318,899 | -- | 5,006,479 |
| Feb 15, 2023 |
Director, President and CEO
Trans History: 29
|
Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300,000 | -- | 841,615 |
| Sep 01, 2020 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300,000 | -- | 300,000 |
| Sep 01, 2020 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4/A | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300,000 | -- | 300,000 |
| May 12, 2021 |
Director, President and CEO
Trans History: 29
|
Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 290,000 | -- | 295,191 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.